Citigroup Maintains Buy on First Horizon, Lowers Price Target to $28
Citigroup analyst Benjamin Gerlinger maintains First Horizon (NYSE:FHN) with a Buy and lowers the price target from $28.5 to $28.
Stocks · News reference
This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Hovde Group Initiates Coverage On First Horizon with Market Perform Rating, Announces Price Target of $25
Hovde Group analyst Edward Najarian initiates coverage on First Horizon (NYSE:FHN) with a Market Perform rating and announces Price Target of $25.
Shares of banking companies are trading lower amid overall market weakness after Fed Chairman Warsh took a hawkish tone in his press conference and Q&A session after the FOMC rate hike.
HC Wainwright & Co. Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Ananda Ghosh initiates coverage on iBio (NASDAQ:IBIO) with a Buy rating and announces Price Target of $7.
8-K filing — iBio, Inc. (IBIO)
Filed: 2026-09-14 AccNo: 0001420720-26-000028 Size: 6 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
iBio, a clinical-stage biotechnology company, announced fiscal year 2026 results marking its transition to clinical development with initiation of Phase 1 trials for IBIO-600, a long-acting anti-myostatin antibody. The company advanced IBIO-610 into IND-enabling studies showing fat-selective weight loss potential and completed successful financings totaling $126 million, extending cash runway into fiscal 2028. R&D expenses increased to $19.6 million from $8.3 million year-over-year, while the company held $88 million in cash and investments.